Suppressing CD33 stimulates phagocytosis, slows plaque growth. A protective CD33 mutation could be a gain of function that activates phagocytosis. The CD33 receptor acts as a dimer. At the 14th ...

Acute myeloid leukemia (AML) is one of the most common forms of cancer in children and adults. CD33, a protein often expressed on the surface of leukemic cells, has been a long-standing target for AML ...

Digital Fusion-Gene expression profiling in acute leukemia (AL): Clinical validation of throughput molecular technology in laboratory medicine. Long-term bosutinib (BOS) for Philadelphia ...

SAN FRANCISCO, CA--(Marketwired - Jun 1, 2015) - Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, today announced positive data from several preclinical studies characterizing the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced an exclusive licensing ...

NEW YORK--(BUSINESS WIRE)--iCell Gene Therapeutics, LLC announced results from a study ongoing at Chengdu Military General Hospital of ICG144, the first CLL1-CD33 Compound CAR T-cell (cCAR) in ...

Signaling through the CD33 receptor counteracts the known beneficial microglial responses to plaques, while clusterin is thought to promote Aβ aggregation. Up until now, these two AD risk factors were ...

Antibody-based therapeutics are valuable tools for the treatment of many human diseases. For example, antibody-based immunotherapies targeting the leukemia antigens CD19 and CD20 have been remarkably ...

SAN FRANCISCO, CA--(Marketwired - Aug 10, 2016) - Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted an ...